meto
Peptide

Sermorelin

A native GHRH analog — the gentlest and most-studied entry point into growth-hormone-axis therapy.

Definition

A 29-amino-acid peptide matching the initial 29 residues of human growth-hormone-releasing hormone. It binds the GHRH receptor in the pituitary, triggering endogenous GH release while maintaining the negative-feedback loop. Described as shorter-acting than modified GHRH analogs with a cleaner regulatory history.

How Meto uses it.

Part of Meto's P2 Muscle Preservation Stack. Also prescribed solo for members preferring a gentler entry. Dosing: nightly subcutaneous on a 5-on / 2-off schedule, typically in 3–6 month cycles with IGF-1 re-checked at month 3. Noted as "the most regulatorily uncomplicated peptide in the GH-axis family."

Safety notes

  • Contraindicated in active malignancy
  • Reduced effectiveness in severe obesity
  • Not for use in pregnancy or lactation
  • Injection-site redness is the most common report

Not a complete list — your clinician reviews your full history, labs and medications during intake. Nothing here replaces that.

Common questions

Sermorelin vs. Tesamorelin — which should I choose?

Sermorelin offers smaller, tighter GH pulses — the gentler entry point; Tesamorelin is indicated when visceral-fat reduction is the specific goal.

Do I still need labs for Sermorelin?

Yes; IGF-1 at baseline and month 3 are the minimum.

$149 panel.
A clinician reads it in 24 hours.

Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.